Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia

Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia

Abstract We aimed to use physiologically based pharmacokinetic (PBPK) modeling and simulation to predict imatinib steady‐state plasma exposure in patients with chronic myeloid leukemia (CML) to investigate variability in outcomes. A validated imatinib PBPK model (Simcyp Simulator) was used to predic...

Full description

Bibliographic Details
Main Authors: Josephine A. Adattini, Jeffry Adiwidjaja, Annette S. Gross, Andrew J. McLachlan
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:Pharmacology Research & Perspectives
Subjects:
adverse drug reactions
drug interactions
early molecular response
exposure‐response
imatinib
physiologically based pharmacokinetic (PBPK)
Online Access:https://doi.org/10.1002/prp2.1082

Internet

https://doi.org/10.1002/prp2.1082

Similar Items